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Succimer Gets TLC
Kenneth Olden, director
of NIEHS, and John
Ruffin, director of NIH's
Office of Minority Health
Research, have announced
the signing of five con-
tracts for a 5-year clinical
trial of succimer, a drug
that reduces blood lead
levels in children. The
purpose of the trial is to
determine whether treating
children with relatively low
blood-lead levels prevents
or reduces associated de-
velopmental delay and
whether the drug is safe.
Walter J. Rogan, project officer
forthe TLC Trial
Walter J. Rogan is the project officer for
the trial, and the coordinating center will
be at Harvard University, with James Ware
as principal investigator. The other princi-
pal investigators and clinical centers are 1)
Frances M. Gill of Joseph Stokes, Jr.
Research Institute, Children's Hospital of
Philadelphia, 2) Julian Chisolm of Ken-
nedy-Krieger Research Institute, Inc., in
consortium with Johns Hopkins Univer-
sity and University of Maryland at Balt-
imore, 3) Richard P. Wedeen of the Uni-
versity of Medicine and Dentistry of New
Jersey, and 4) Robert L.
Bornschein of the Univer-
sity ofCincinnati.
Each of the centers will
treat about 250 children
18-24 months of age and
follow them for up to 4
years. All children will have
the lead dust and paint in
their homes cleaned up and
will receive vitamin and
mineral supplements so
they meet current recom-
mended daily allowances,
especially for zinc and calci-
um. The Toxicity of Lead
in Children (TLC) clinical
trial will cost approximately
James H. Ware, Harvard
University
$30 million over the next 5 years.
Recent studies oflead-exposed children
show that blood-lead levels once thought
to be harmless cause significant delays in
motor control and intellectual develop-
ment. These developmental delays may
impede social development and readiness
for school. The TLC trial will determine if
succimer reduces or eliminates such devel-
opmental delays.
Succimer is a relatively new drug that
has not been adequately tested clinically.
It is the first available drug of its type (a
chelating agent) since 1950,
and it can be orally adminis-
tered at home. Succimer ap-
pears to be relatively safe and
may not cause as much loss of
elements needed by the body,
such as zinc and iron, as do
other drugs.
The TLC trial is made
possible through an agreement
between NIEHS
and the Office of
Research on Min-
ority Health,
which allocates $5
million per year
for five years to
address minority
health concerns related to the
environment. The agreement
was signed in March by Olden
and Ruffin.
"This clinical trial could
have tremendous impact on
the health of minority chil-
dren. Lead poisoning is just
one health concern that dis-
proportionately affects minori-
ties. By joining forces on this
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issue and others, the ORMH and the
NIEHS are working to reduce the burden
of illness shouldered by min-
orityAmericans," said Ruffin.
In a recent article in Pre-
ventive Medicine, Olden not-
ed "Children ingest their en-
vironment. When that envi-
ronment is contaminated by
lead, they ingest lead. They
absorb and transport lead
across their gastrointestinal
tracts and into their blood-
streams about six times more
efficiently than adults do. A
major environmental health
issue for children today is the
extremely high prevalence of
unacceptable exposure to
lead, especially in inner cities,
but occurring throughout the country.
This clinical trial will address the terrible
toll lead takes on our children's futures."
Predicting Carcinogenicity
In response to the publication of a set of
predictions and a novel challenge by
Raymond Tennant and colleagues at
NIEHS and John Ashby at Zeneca, experts
attempted to predict the outcomes of 44
rodent cancer bioassays conducted by the
National Toxicology Program before the
results were known. In May, about 200
scientists and other professionals from all
over the the world met at NIEHS, home
base of the NTP, to review 10 separate
attempts to predict rodent bioassay results.
The purpose of the workshop, "Pre-
dicting Chemical Carcinogenesis in Ro-
dents," was to assess prediction methods. If
carcinogenicity could be predicted, chemi-
cals could be prioritized for study and
warnings issued for exposure to certain
chemicals until cancer
studies could be done. In
the first part of the work-
shop, participants gave
overviews of the methods
they used to make predic-
tions. In the second part of
the workshop, organiza-
tions that use study results
(regulatory agencies, re-
search institutions, etc.)
discussed the strengths and
weaknesses of the various
methods. In a summary of
the workshop, Michael
Shelby of NIEHS gave an
overview, citing both the
positive aspects of the pre-
diction methods and the
many hurdles yet to be overcome.
Shelby pointed out that there were at
least three strengths evident in the predic-
tion efforts. First, some of the systems
described at the workshop were successful
in predicting strongly carcinogenic chemi-
cals and some clearly noncarcinogenic
chemicals; second, the systems performed
better with certain classes ofchemicals; and
finally, all the systems have the potential to
be improved.
A major problem in optimizing the
performance of the various prediction
methods is the lack ofdetailed information
on mechanisms of carcinogenicity. An
understanding of the bioavailability of a
given chemical, as well as possible changes
in the metabolism of the chemical during
aging, would be beneficial in predicting
carcinogenicity. Likewise, improvements in
the ability to monitor early events in the
carcinogenic process such as genetic insta-
bility, changes in gene expression, and acti-
vation of oncogenes would help establish
structure-activity relationships. Research-
ers at the workshop were optimistic about
the continued evolution ofmethods to pre-
dict a variety ofbiological activities.
Other issues confronted in the work-
shop included changes in tumor rates of
control animals over time, the unknown
reproducibility of most rodent bioassays,
and the fact that most models used in the
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